Long-Term Beneficial Effect of Tacrolimus Conversion on Renal Transplant Recipients

References

• Cecka, J.; Cho, Y.; Terasaki, P. Analysis of the UNOS scientific renal transplant registry at three years—early events affecting transplant success. Transplantation 1992, 53, 59–64. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Frey, D.; Matas, A.; Gillingham, K J.; Canafax, D.; Payne, W D.; Dunn, D L.; , et al. Sequential therapy—a prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients. Transplantation 1992, 54, 50–56. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Graham, R. Cyclosporine: mechanisms of action and toxicity. Clevel. Clin. J. Med. 1994, 61, 308–313. [CSA]
   PubMed Web of Science ®Google Scholar
• Kohnle, M.; Zimmermann, U.; Lutkes, P.; Albrecht, K H.; Philipp, T.; Heemann, U. Conversion from cyclosporine A to tacrolimus after kidney transplantation due to hyperlipidemia. Transplant. Int. 2000, 13(Suppl.)S345–S348. [CSA], [CROSSREF]
   Google Scholar
• Tanabe, K.; Ishikawa, N.; Tokumoto, K.; Takahashi, K.; Oshima, T.; Fuchinoue, S.; , et al. Factors affecting long-term renal allograft survival in cyclosporine-treated kidney transplants. Transplant. Proc. 1998, 30, 1805–1809. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Goto, T.; Kino, T.; Hatanaka, H.; Okuhara, M.; Kohsaka, M.; Aoki, H.; , et al. FK506: historical perspectives. Transplant. Proc. 1991, 23, 2713–2717. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kaplan, B.; Schold, J D.; Meier-Kriesche, H U. Long-term graft survival with neoral and tacrolimus: a paired kidney analysis. J. Am. Soc. Nephrol. 2003, 14, 2980–2984. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kelly, D.; Jara, P.; Rodeck, B.; Lykavieris, P.; Burdelski, M.; Becker, M.; , et al. Tacrolimus and steroids versus cyclosporine microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomized European multicenter trial. Lancet 2004, 364, 1054–1061. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Urbizu, J M.; Zarraga, S.; Gomez-Ullate, P.; Amenabar, J J.; Gainza, F I.; Lampreabe, I.; , et al. Safety and efficacy of tacrolimus rescue therapy in 55 kidney transplant patients treated with cyclosporine. Transplant. Proc. 2003, 35, 1704–1705. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Peters, D H.; Fitton, A.; Plosker, G L.; Faulds, D. Tacrolimus: a review of its pharmacology and therapeutic potential in hepatic and renal transplantation. Drugs 1993, 46, 746–794. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Shu, K H.; Cheng, C H.; Wu, M J.; Lian, J D.; Huang, C C.; Chu, S H.; , et al. A multicenter trial of FK506 as rescue therapy for renal transplant recipients in Taiwan. Transplant. Proc. 1998, 30, 3584–3586. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Lo, J C.; Chertow, G M.; Go, A S.; Hsu, C Y. Increased prevalence of subclinical and clinical hypothyroidism in persons with chronic kidney disease. Kidney Int. 2005, 67, 1047–1052. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Levey, A S.; Greene, T.; Kusek, J W.; Beck, G J. A simplified equation to predict glomerular filtration rate from serum creatinine. J. Am. Soc. Nephrol. 2000, 11, 155A. [CSA]
   Google Scholar
• Levey, A S.; Bosch, J P.; Lewis, J B.; , et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann. Intern. Med. 1999, 130, 461–470. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Woodle, E S.; Perdrizet, G A.; So, S.; Jendrisak, M D.; White, H M.; Marsh, J W. FK 506 rescue therapy: early conversion improves efficacy. Transplant. Proc. 1993, 25, 1990–1991. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Jordan, M L.; Naraghi, R.; Shapiro, R.; Smith, D.; Vivas, C A.; Scantlebury, V P.; , et al. Tacrolimus for rescue of refractory renal allograft rejection. Transplant. Proc. 1998, 30, 1257–1260. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Manu, M A.; Tanabe, K.; Ishikawa, N.; Tokumoto, T.; Oshima, T.; Shinmura, H.; , et al. Tacrolimus rescue for resistant rejection, chronic rejection and immunoglobulin A nephropathy of renal allografts under primary cyclosporine A immunosuppression. Transplant. Proc. 1999, 31, 2853–2855. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Budde, K.; Smettan, S.; Fritsche, L.; Waiser, J.; Neumayer, H H. Five-year outcome of tacrolimus rescue therapy in late rejection after renal transplantation. Transplant. Proc. 2002, 34, 1594–1596. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Morrissey, P E.; Gohh, R.; Shaffer, D.; Crosson, A.; Madras, P N.; Sahyoun, A I.; , et al. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. Transplantation 1997, 63, 845–848. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Olyaei, A J.; de Mattos, A M.; Bennett, W M. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr. Opin. Crit. Care 2001, 7, 384–389. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Vieira, J M.J.; Noronha, I L.; Malheiros, D M.; Burdmann, E A. Cyclosporine-induced interstitial fibrosis and arteriolar TGF-beta expression with preserved renal blood flow. Transplantation 1999, 68, 1746–1753. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Baan, C C.; van Riemsdijk-van Overbeeke, I C.; Balk, A H.; Vantrimpont, P M.; Mol, W M.; Knoop, C J.; , et al. Conversion from cyclosporine A to tacrolimus is safe and decreases blood pressure, cholesterol levels and TGF-β1 type I receptor expression. Clin. Transplant. 2001, 15, 276–283. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Ebbs, A.; Pan, F.; Wynn, C.; Erickson, L.; Kobayashi, M.; Jiang, H. Tacrolimus treats ongoing allograft rejection by inhibiting interleukin-10 mediated functional cytotoxic cell infiltration. Transplant. Proc. 2002, 34, 1378–1381. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Jiang, H.; Yang, X F.; Wynn, C.; Soriano, R.; Krishnan, K.; Fujimura, T.; , et al. IL-10: a tacrolimus-specific cytotoxic mediator in ongoing allograft rejection. Transplant. Proc. 2001, 33, 510–513. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Jiang, H.; Yang, X.; Soriano, R.; Fujitus, T.; Kobayashi, M. Inhibition of IL-10 by FK 506 may be responsible for overcoming ongoing allograft rejection in the rat. Transplant. Proc. 1999, 31, 1203–1205. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Jiang, H.; Wynn, C.; Pan, F.; Ebbs, A.; Erikson, L M.; Kobayashi, M. Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production. Transplantation 2002, 73, 1808–1817. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Jordan, M L.; Shapiro, R.; Vivas, C A.; Scantlebury, V P.; Rhandhawa, P.; Carrieri, G.; , et al. FK 506 “rescue” for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 1994, 57, 860–865. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar